- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the company had requested a “conditional” emergency use authorization from the Food and Drug
Administration for an experimental Covid-19 antibody treatment, despite its failure in a late-stage clinical trial. But a “conditional” EUA — as described by CytoDyn’s CEO — does not exist.
“If you look at the law there is no such thing. You can certainly say that,” an FDA official told STAT on Wednesday, in response to the claims made by CytoDyn. The official asked not to be
identified because of rules barring the agency from discussing regulatory matters involving unapproved drugs. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE
TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans
To read the rest of this story subscribe to STAT+. Subscribe
